Cite
HARVARD Citation
Weidinger, S. et al. (n.d.). 353 Amlitelimab reduces serum IL-13 in a phase 2a clinical trial in atopic dermatitis without impacting T-cell expansion in a T-cell recall assay. British journal of dermatology. p. . [Online].